Bosutinib: a new, safer TKI for frontline CML

The recent FDA approval of bosutinib makes it the fourth inhibitor for the frontline treatment of chronic myeloid leukemia (CML), as Michael Mauro, MD, of Memorial Sloan Kettering Cancer Center, New Y... Author: VJHemOnc Added: 08/15/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts